Showing results (201-210 of 368) with videos related to
Sort By:
Pageof 37
JAMA Neurology|October 5, 2017
Targeting Pioglitazone Hydrochloride Therapy After Stroke or Transient Ischemic Attack According to Pretreatment Risk for Stroke or Myocardial InfarctionWalter N Kernan, Catherine M Viscoli, Jennifer L Dearborn, et al.Circulation|April 14, 2020
Clinical Management of Stable Coronary Artery Disease in Patients With Type 2 Diabetes Mellitus: A Scientific Statement From the American Heart AssociationSuzanne V Arnold, Deepak L Bhatt, Gregory W Barsness, et al.Cardiovascular Diabetology|June 20, 2014
Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)Bernard Zinman, Silvio E Inzucchi, John M Lachin, et al.JCI Insight|October 20, 2017
Blunted rise in brain glucose levels during hyperglycemia in adults with obesity and T2DMJanice J Hwang, Lihong Jiang, Muhammad Hamza, et al.ESC Heart Failure|October 4, 2021
Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA-REG OUTCOME trialDavid Fitchett, Silvio E Inzucchi, Bernard Zinman, et al.Diabetes, Obesity & Metabolism|December 9, 2022
Reduction of cardiac adipose tissue volume with short-term empagliflozin treatment in patients with type 2 diabetes: A substudy from the SIMPLE randomized clinical trialNiels H Brandt-Jacobsen, Mikkel Jürgens, Philip Hasbak, et al.Diabetes|January 21, 2022
Randomized Controlled Trial of the Hemodynamic Effects of Empagliflozin in Patients With Type 2 Diabetes at High Cardiovascular Risk: The SIMPLE TrialEmil Wolsk, Mikkel Jürgens, Morten Schou, et al.European Journal of Heart Failure|March 22, 2019
A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF)John J V McMurray, David L DeMets, Silvio E Inzucchi, et al.European Journal of Heart Failure|July 17, 2019
The Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure (DAPA-HF) trial: baseline characteristicsJohn J V McMurray, David L DeMets, Silvio E Inzucchi, et al.Journal of Cardiac Failure|August 8, 2021
Empagliflozin in Heart Failure With Predicted Preserved Versus Reduced Ejection Fraction: Data From the EMPA-REG OUTCOME TrialGianluigi Savarese, Alicia Uijl, Lars H Lund, et al.Pageof 37